Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Gross Margin (2017 - 2020)

Ironwood Pharmaceuticals' Gross Margin history spans 7 years, with the latest figure at 99.23% for Q4 2020.

  • On a quarterly basis, Gross Margin rose 795.0% to 99.23% in Q4 2020 year-over-year; TTM through Dec 2020 was 99.19%, a 644.0% increase, with the full-year FY2020 number at 99.19%, up 477.0% from a year prior.
  • Gross Margin hit 99.23% in Q4 2020 for Ironwood Pharmaceuticals, down from 100.0% in the prior quarter.
  • Over the last five years, Gross Margin for IRWD hit a ceiling of 100.0% in Q2 2020 and a floor of 10631.5% in Q4 2018.
  • Historically, Gross Margin has averaged 575.32% across 4 years, with a median of 95.61% in 2018.
  • Biggest five-year swings in Gross Margin: plummeted -1072196bps in 2018 and later surged 1072278bps in 2019.
  • Tracing IRWD's Gross Margin over 4 years: stood at 90.46% in 2017, then tumbled by -11852bps to 10631.5% in 2018, then soared by 101bps to 91.28% in 2019, then grew by 9bps to 99.23% in 2020.
  • Business Quant data shows Gross Margin for IRWD at 99.23% in Q4 2020, 100.0% in Q3 2020, and 100.0% in Q2 2020.